Oral News and Research

RSS

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has achieved enrolled of over 400 subjects in its pivotal global Phase III study of its flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product designed to replace prandial injections of insulin.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Health Canada approves BDSI's NDS for ONSOLIS

BioDelivery Sciences International, Inc. today announced the approval of a New Drug Submission (NDS) by Health Canada, the regulatory authority in Canada, for ONSOLIS (fentanyl buccal soluble film) in the management of breakthrough pain in opioid-tolerant adult patients with cancer. ONSOLIS is the first product approved in Canada for this indication.

10 May 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

GSK participates in FDA advisory committee's rotavirus vaccine meeting

GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.

10 May 2010

50 years of the Contraceptive Pill

The Contraceptive Pill celebrated its 50th birthday on Mother's Day this year. The Pill was approved by the FDA in 1960 giving greater control to women about when they would like to give birth. The choice was supposed to help eliminate unwanted pregnancies and help couples grow closer. It was also supposed to help the couple financially by not placing burdens of early children on them.

9 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

NewCardio, Inc., a cardiac diagnostic technology provider, will unveil its patented CardioBip technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

7 May 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Warner Chilcott plc today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter.

7 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

First clinical trial results of camera chip implanted under retina presented at 2010 ARVO meeting

Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of findings from their first clinical trial in which blind patients were able to view and focus on objects as their eye and head naturally moved as opposed to needing to constantly move their head to scan a scene, which is the case for other implants in which a camera is mounted to the patient's head.

7 May 2010

APA president highlights challenges faced in child healthcare

Whether you live in Haiti or in Harlem, the impact of poverty is the same. Children suffer from poor nutrition, environmental degradation, violence and poor development in the U.S. just as they do in less developed nations, and the consequences can be equally profound, according to Dr. Danielle Laraque, MD, president of the Academic Pediatric Association (APA).

7 May 2010

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals plc, a pharmaceutical development company, today announces that it has been granted a further U.S. Patent, increasing the protection for their lead product, Orazol™.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

Hepcidin is found in various biological fluids, says new research

Recent studies have highlighted the importance of hepcidin in iron metabolism, particularly anaemia of chronic disease and iron overload. There have also been reports of its expression in various proinflammatory disorders and various organs, linking it to innate immunity and iron metabolism.

7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Oral News and Research

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Health Canada approves BDSI's NDS for ONSOLIS

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

GSK participates in FDA advisory committee's rotavirus vaccine meeting

50 years of the Contraceptive Pill

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

First clinical trial results of camera chip implanted under retina presented at 2010 ARVO meeting

APA president highlights challenges faced in child healthcare

Merrion Pharmaceuticals increases patent protection for Orazol

Natazia tablets receive FDA approval for prevention of pregnancy

Hepcidin is found in various biological fluids, says new research

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Genzyme to initiate $2 billion stock buyback

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News